Christelle Haziza, PhD
Philip Morris Products S.A.
27
0
24
N/A
0
10
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+44 more interventions
Analytics
Trial Phases
No phase data
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Jonathan Austin, MD
High Point Clinical Trials Center
Shared therapeutic areas:
Worked with same sponsors:
William Smith, MD
NOCCR
Shared therapeutic areas:
Worked with same sponsors:
Frank Lee, MD
Inflamax Research - Neptune
Shared therapeutic areas:
Worked with same sponsors:
Armin Schultz, MD
CRS Clinical Research Services Mannheim GmbH
Shared therapeutic areas:
Worked with same sponsors:
Stephanie Powell, MD
PMG Research of Bristol
Shared therapeutic areas:
Worked with same sponsors:
Mark Adams, MD
Central Kentucky Research Associate
Shared therapeutic areas:
Worked with same sponsors:
Fumimasa Nobuoka, MD
Ageo Medical Clinic
Shared therapeutic areas:
Worked with same sponsors:
Danielle Armas, MD
Celerion Arizona
Shared therapeutic areas:
Worked with same sponsors:
Isabel Kuhare-Arcure, MD
Midwest Clinical Research
Shared therapeutic areas:
Worked with same sponsors:
John Rubino, MD
PMG Research of Raleigh
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (27)
Showing 20 of 27 trials
Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants
Pharmacokinetics and Pharmacodynamics of THS With LEVIA Compared to THS With TEREA and to Cigarettes
Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)
Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease
Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.
Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity
Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P
Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants
Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure
Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation
Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)